ECSP088636A - Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer - Google Patents

Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer

Info

Publication number
ECSP088636A
ECSP088636A EC2008008636A ECSP088636A ECSP088636A EC SP088636 A ECSP088636 A EC SP088636A EC 2008008636 A EC2008008636 A EC 2008008636A EC SP088636 A ECSP088636 A EC SP088636A EC SP088636 A ECSP088636 A EC SP088636A
Authority
EC
Ecuador
Prior art keywords
sialic acid
antigens
des
acetyl
antibodies
Prior art date
Application number
EC2008008636A
Other languages
English (en)
Inventor
Gregory R Moe
Charles Paul Plested
Original Assignee
Childrens Hosp & Res Center Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp & Res Center Oakland filed Critical Childrens Hosp & Res Center Oakland
Publication of ECSP088636A publication Critical patent/ECSP088636A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona en general composiciones, y métodos relacionados con el diagnóstico y/o el tratamiento de cánceres que tengan un antígeno de ácido siálico des-N-acetilado de superficie celular, por ejemplo, un gangliósido cuando menos parcialmente des-N-acetilado, y/o una proteína de superficie celular modificada por ácido siálico des-N-acetilado
EC2008008636A 2005-12-23 2008-07-18 Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer ECSP088636A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75384705P 2005-12-23 2005-12-23

Publications (1)

Publication Number Publication Date
ECSP088636A true ECSP088636A (es) 2008-08-29

Family

ID=38218629

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008636A ECSP088636A (es) 2005-12-23 2008-07-18 Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer

Country Status (10)

Country Link
EP (1) EP1976554B1 (es)
JP (1) JP5384941B2 (es)
KR (1) KR101462963B1 (es)
AU (1) AU2006331634B2 (es)
BR (1) BRPI0620453A2 (es)
CA (1) CA2634755C (es)
CR (1) CR10143A (es)
EC (1) ECSP088636A (es)
MX (1) MX2008008185A (es)
WO (1) WO2007075921A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5702600B2 (ja) * 2007-07-03 2015-04-15 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド オリゴシアル酸誘導体、製造方法および免疫学的使用
JP5523313B2 (ja) * 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
US8999954B2 (en) 2007-07-03 2015-04-07 Childern's Hospital & Research Center at Oakland Inhibitors of polysialic acid de-N-acetylase and methods for using the same
CA2721169A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
FR2955321B1 (fr) 2010-01-21 2012-02-10 Rhodia Operations Procede d'oxydation d'hydrocarbures
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
MX390928B (es) 2014-01-24 2025-03-19 Pneumagen Ltd Compuestos inmunomoduladores.
GB201616007D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Novel Adjuvants
GB201616006D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Cell modulation
GB201616009D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Treatment and/or prevention of sepsis
CN112795583A (zh) * 2020-11-16 2021-05-14 上海大学 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922059B1 (en) * 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
CA2279134A1 (en) * 1999-07-29 2001-01-29 Tianmin Liu Novel strategy for carbohydrate-based therapeutic vaccines
WO2006002402A2 (en) * 2004-06-23 2006-01-05 Children's Hospital & Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response

Also Published As

Publication number Publication date
BRPI0620453A2 (pt) 2011-11-08
JP5384941B2 (ja) 2014-01-08
WO2007075921A3 (en) 2008-08-14
JP2009525947A (ja) 2009-07-16
AU2006331634B2 (en) 2013-01-10
CR10143A (es) 2008-10-10
AU2006331634A1 (en) 2007-07-05
WO2007075921A2 (en) 2007-07-05
KR101462963B1 (ko) 2014-11-19
CA2634755C (en) 2018-03-27
KR20080091777A (ko) 2008-10-14
EP1976554B1 (en) 2016-11-16
MX2008008185A (es) 2008-11-14
EP1976554A4 (en) 2010-05-12
EP1976554A2 (en) 2008-10-08
CA2634755A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CL2022002448A1 (es) Constructos de anticuerpo para flt3 y cd3 (divisional sol.: 201800269)
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
UA105760C2 (uk) Антитіло проти bst2
BRPI0810096A2 (pt) Anticorpo anti-epcam e seus usos
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
AR059809A1 (es) Anticuerpos anti-5t4 y sus usos
AR044927A1 (es) Metodos y composiciones para tratar la artritis reumatoidea
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
CR8231A (es) Anticuerpos rg1 y uso de los mismos
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
SG163583A1 (en) Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
AR071304A1 (es) Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen